Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy
- 234 Downloads
Survival in lung cancer patients is genetically determined. Single nucleotide polymorphisms (SNPs) in DNA repair genes are observed to play a critical role in survival as DNA repair itself can behave as double-edged sword. We aim to explore the association of DNA repair gene XRCC1 in survival and clinical outcomes for North Indian population. Blood sample from patients diagnosed with lung cancer was taken. DNA isolation and genotyping were performed for the SNPs of XRCC1 gene. Further, patients were followed up through telephonic conversation after every 2 months for 3 years. Statistical analysis was carried out using Kaplan–Meier to determine the median survival time (MST) and Cox proportional regression model to determine the hazards ratio. Further, logistic regression was used to calculate to calculate the objective response. The mutant genotype for XRCC1 399 is observed to have a better survival (MST = 9.6). Histological stratification did not reveal any association for any SNP except for SCLC subtype in XRCC1 632 with an increased death rate (HR 3.08, p = 0.02). On stratification according to chemotherapy regimen administered; cisplatin/carboplatin + docetaxel was observed to increase survival for XRCC1 399 mutant genotype (AA) (HR 0.26, p = 0.05). Cisplatin/carboplatin + irinotecan increased survival in both heterozygotes (GA) and combined variants (GA + AA) (HR 0.22, p = 0.014; HR 0.23, p = 0.012). The polymorphic variants within the XRCC1 gene have found to play an important role in overall survival of lung cancer patients undergoing specific chemotherapy regimen.
KeywordsLung cancer Single nucleotide polymorphism XRCC1 Overall survival Hazards rate Chemotherapy
Squamous cell carcinoma
Small cell lung carcinoma
Non-small cell lung carcinoma
DNA repair capacity
Eastern cooperative oncology group
Karnofsky’s response status
Response evaluation criteria in solid tumors
We would like to express our gratitude to all the subjects who participated in this current study. This work was supported by grant from the Indian Council of Medical Research, New Delhi, India (Grant No. 5/13/126/2011/NCD-III).
Compliance with ethical standards
Conflict of interest
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.International Agency for Research on Cancer, Lung Cancer. Estimated Incidence, Mortality and Prevalance Worldwide in 2012. http://globocan.iarc.fr/Pages/factsheets_cancer.aspx. Accessed 10 May 2016.
- 3.National Comprehensive Cancer Network, Inc., 2016. https://www.nccn.org/professionals/physician_gls/recently_updated.asp.
- 8.Wei Q, Cheng L, Hong K, et al. Reduced DNA repair capacity in lung cancer patients. Can Res. 1996;56:4103–8.Google Scholar
- 10.Dexheimer TS, DNA repair pathways and mechanisms 2013.Google Scholar
- 25.Navneet S, Ashutosh A, et al. Association of graded folic acid supplementation and total plasma homocysteine levels with hematological toxicity during first-line treatment of nonsquamous NSCLC patients with pemetrexed-based chemotherapy. Am J Clin Oncol. 2014. doi: 10.1097/COC.0000000000000111.Google Scholar
- 28.Zhang Z, Wan J, Jin X, et al. Genetic polymorphisms in XRCC1, APE1, ADPRT, XRCC2 and XRCC3 and risk of chronic benzene poisoning in a Chinese occupational population. Cancer Epidemiol Biomarkers Prev. 2005;2614–20.Google Scholar
- 30.Liao W, Shih J, Chang G, et al. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. JTO Acquis. 2012;7(6):973–81.Google Scholar
- 44.Hu HQ, Wang F, Du X et al. Genetic variability of XRCC1 influences the treatment outcome of gastric cancer. Genet Mol Res 2016;15.Google Scholar
- 45.Yuan Z, Li J, Hu R, et al. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy. Nat Publ Gr Sci Rep. 2015;5:16482.Google Scholar